BRN 2 Invade

Gaurav Pathria; Ze'ev A. Ronai

doi:10.1016/j.ccell.2018.06.010

BRN 2 Invade

Gaurav Pathria, Ze'ev A. Ronai

Research output: Contribution to journal › Short survey › peer-review

2 Scopus citations

Abstract

One of the remaining challenges in treating melanoma is its strong propensity to metastasize. Thus, there is considerable interest in understanding the alterations that drive progression of the disease. In this issue of Cancer Cell, Shain et al. and Zheng et al. provide insights implicating p16^INK4A in melanoma invasiveness. One of the remaining challenges in treating melanoma is its strong propensity to metastasize. Thus, there is considerable interest in understanding the alterations that drive progression of the disease. In this issue of Cancer Cell, Shain et al. and Zheng et al. provide insights implicating p16^INK4A in melanoma invasiveness.

Original language	English
Pages (from-to)	1-3
Number of pages	3
Journal	Cancer Cell
Volume	34
Issue number	1
DOIs	https://doi.org/10.1016/j.ccell.2018.06.010
State	Published - 9 Jul 2018
Externally published	Yes

Access to Document

10.1016/j.ccell.2018.06.010

Cite this

@article{c6e72482e92d45f8937e868442760b2a,

title = "BRN 2 Invade",

abstract = "One of the remaining challenges in treating melanoma is its strong propensity to metastasize. Thus, there is considerable interest in understanding the alterations that drive progression of the disease. In this issue of Cancer Cell, Shain et al. and Zheng et al. provide insights implicating p16INK4A in melanoma invasiveness. One of the remaining challenges in treating melanoma is its strong propensity to metastasize. Thus, there is considerable interest in understanding the alterations that drive progression of the disease. In this issue of Cancer Cell, Shain et al. and Zheng et al. provide insights implicating p16INK4A in melanoma invasiveness.",

author = "Gaurav Pathria and Ronai, {Ze'ev A.}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = jul,

day = "9",

doi = "10.1016/j.ccell.2018.06.010",

language = "English",

volume = "34",

pages = "1--3",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - BRN 2 Invade

AU - Pathria, Gaurav

AU - Ronai, Ze'ev A.

PY - 2018/7/9

Y1 - 2018/7/9

N2 - One of the remaining challenges in treating melanoma is its strong propensity to metastasize. Thus, there is considerable interest in understanding the alterations that drive progression of the disease. In this issue of Cancer Cell, Shain et al. and Zheng et al. provide insights implicating p16INK4A in melanoma invasiveness. One of the remaining challenges in treating melanoma is its strong propensity to metastasize. Thus, there is considerable interest in understanding the alterations that drive progression of the disease. In this issue of Cancer Cell, Shain et al. and Zheng et al. provide insights implicating p16INK4A in melanoma invasiveness.

AB - One of the remaining challenges in treating melanoma is its strong propensity to metastasize. Thus, there is considerable interest in understanding the alterations that drive progression of the disease. In this issue of Cancer Cell, Shain et al. and Zheng et al. provide insights implicating p16INK4A in melanoma invasiveness. One of the remaining challenges in treating melanoma is its strong propensity to metastasize. Thus, there is considerable interest in understanding the alterations that drive progression of the disease. In this issue of Cancer Cell, Shain et al. and Zheng et al. provide insights implicating p16INK4A in melanoma invasiveness.

UR - http://www.scopus.com/inward/record.url?scp=85049048609&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2018.06.010

DO - 10.1016/j.ccell.2018.06.010

M3 - Short survey

C2 - 29990495

AN - SCOPUS:85049048609

SN - 1535-6108

VL - 34

SP - 1

EP - 3

JO - Cancer Cell

JF - Cancer Cell

IS - 1

ER -

BRN 2 Invade

Abstract

Access to Document

Fingerprint

Cite this